Neuroblastoma (NB) is a lethal tumor of childhood for which therapy has improved little over the past decades and which is assumed to benefit from insights into perturbed signaling pathways. Recently, ALK was discovered as a drugable oncogene in NB. Currently, clinical trials have been initiated in order to evaluate the efficacy of these compounds. However, our currently insights in the perturbed signaling down stream of ALK is limited as is our knowledge of other signaling components cooperating or interacting with ALK. Such knowledge is crucial for optimal design and monitoring of molecular therapy, such as prediction of respons to therapy, design of multitarget molecular therapy to prevent resistance etc. To achieve this goal, we will exploit powerful state-of-the-art genome/proteome wide analyses in the context of in vitro cellular model systems and mouse models combined with integrated genome and systems biology analyses.